This site uses cookies to ensure the best viewing experience for our readers.
Medtech Investment Firm Accelmed Backs Reflux Therapy Company EndoGastric

Brief

Medtech Investment Firm Accelmed Backs Reflux Therapy Company EndoGastric

EndoGastric develops incisionless procedural therapy for gastroesophageal reflux disease

Meir Orbach  :  2019-05-28T15:27:03..
Israel-based medtech investment firm Accelmed Growth Partners has joined a funding round of about $45 million for Redmond, Washington-based medical device company EndoGastric Solutions Inc., the two announced Tuesday. Of the sum, Accelmed invested $15 millions. Other participants in the round include Canaan Partners, Chicago Growth Partners, and De Novo Ventures.

Founded in 2003, EndoGastric develops incisionless procedural therapy for gastroesophageal reflux disease.

Based in Israeli central town Herzliya, with additional offices in New York, Accelmed has $350 million in assets under management. Founded in 2009 by Israeli businessmen Mori Arkin and Uri Geiger, the firm invests in small and mid-cap private and public companies in the digital health industry.

Accelmed Co-Founder and Managing Partner Uri Geiger. Photo: PR Accelmed Co-Founder and Managing Partner Uri Geiger. Photo: PR Accelmed Co-Founder and Managing Partner Uri Geiger. Photo: PR
share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS